Indian healthcare AI startup Qure.AI aiming for IPO in two years, CEO says
By Rishika Sadam
(Reuters) -Qure.AI, an India-based startup providing artificial intelligence tools to healthcare firms, is aiming to turn profitable in the next financial year and for an initial public offer (IPO) in two years, its CEO told Reuters.
The company, founded in 2016 and largely backed by AI firm Fractal Analytics, counts Peak XV Partners and Novo Nordisk's Novo Holdings among its investors, and has raised $125 million in funding so far, CEO Prashant Warier said.
"We look to break even and be profitable next financial year. As we sort of get to that break-even...we can start planning. And maybe in two-and-a-half years or two years is the earliest we can do an IPO," he said last week.
He declined to elaborate on the firm's valuation. The firm was valued at $264 million as of November 2024, according to data from market intelligence platform Tracxn.
Qure.AI provides AI solutions in diagnostics for early detection of tuberculosis, lung cancer and stroke risks. Its global clients include AstraZeneca, and Medtronic and Johnson and Johnson MedTech in India.
The global market for AI in healthcare, valued at $14.92 billion in 2024, is expected to grow to $110 billion by 2030, according to market estimates.
AI is being rapidly adopted by healthcare service providers around the world for early detection of diseases and to streamline work for overburdened professionals, according to industry experts.
"We're growing at a rate of 60%-70% every year (in revenue) and I think we probably will accelerate in the next five years," Warier said, adding that they serve around 15 million patients annually.
QureAI derives about 25% of revenue from the United States, which is its largest market, and is also eyeing expansion in the market with further partnerships, he said.
The company also is focusing on on low-and middle-income countries in Latin America and Africa. India, however, is a much smaller market for the firm, contributing less than 5% of revenue.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
28 minutes ago
- Medscape
Avoiding the COVID Shot Talk? Here's What to Do
Do you hesitate to bring up COVID vaccines with your patients? You're not alone — and experts said these conversations are becoming less common in routine care. The reasons are complex, ranging from short visit times and shifting clinical priorities to the health attitudes of both physicians and patients — and something Arthur Caplan, PhD, head of the Ethics Division at NYU Grossman School of Medicine, New York City, called 'COVID exhaustion.' Arthur Caplan, PhD 'There is a feeling that everybody who's going to get COVID either got it or got vaccinated or doesn't want [the shot],' said Caplan. But your silence can leave patients feeling unsure about what to do. New CDC guidance for COVID boosters — and even baseline vaccination — for healthy people (including children) has shifted toward shared clinical decision-making. What does that mean? According to the now-fired CDC vaccine advisory panel, shared clinical decision-making means 'informed by the best available evidence of who may benefit from vaccination; the individual's characteristics, values, and preferences; the healthcare provider's clinical discretion; and the characteristics of the vaccine being considered.' The panel added, 'There is not a prescribed set of considerations or decision points in the decision-making process.' In other words, you're on your own. All the major US physician organizations still recommend the shots for everyone 6 months and older. Amid widespread misinformation about the vaccines' risks and lack of benefit, there's another reason providers should bring them up — protecting those most at risk for severe COVID, Caplan said. 'We're so individualistic, so focused on personal choice, so focused on the individual, that we're undercutting a moral basis or the ethical basis for vaccination, which is the community,' he said. Surveys consistently showed that more people say they plan to get COVID vaccines than actually do, and the barriers throttling that conversion rate are unclear. If you find yourself hesitating to bring up the COVID vaccine, ask yourself why — so you can thoughtfully address that hesitation in practice. Why You Don't Bring Up COVID Shots With Healthy Patients Timothy Callaghan, PhD First, the elephant in the room: Many people are hesitant to talk about COVID vaccines because of how politically charged the topic has become, and clinicians are no exception. 'Physicians may be hesitant to bring up any topics that might induce partisan beliefs and lead people to be less trusting of seeking out medical care,' said Timothy Callaghan, PhD, associate professor at the Boston University School of Public Health, Boston, and an expert in vaccine hesitancy and health behavior. 'They might forego discussing those to make sure they're doing everything they can to keep patients engaged with the healthcare system so that they can keep them safe and healthy.' Jen Brull, MD Another key challenge is the topic's complexity. 'Sometimes those conversations need to be lengthy to let people feel comfortable that their questions were answered, their fears were addressed, the confusion was resolved,' said Jen Brull, MD, president of the American Academy of Family Physicians. 'In a 10- or 15-minute office visit, you might say, 'Do I want to open this Pandora's box today? Do I have time to do this? How late am I?'' In the pediatric setting, parents' perception is often that COVID is generally well-tolerated by healthy children, and they view COVID vaccines differently than they do vaccines that are required for school, said Jesse Hackell, MD, chair of the American Academy of Pediatrics Committee on Pediatric Workforce. 'If I've got a kid who needs the measles vaccine and the COVID vaccine, I don't want to poison the atmosphere for the measles vaccine by pushing the COVID vaccine,' Hackell said. Your move? Don't wait for the Pandora's box moment. Start preparing now. Your Vaccine Recommendation Plan You may not be thinking about your fall vaccine campaign yet, but now is the time to plan — before an unexpected surge leaves you unprepared. Jesse Hackell, MD One exception to fall timing is baseline vaccination of 6-month-olds, Hackell said. Data show the risk for severe illness during the first year is high, so these babies should get vaccinated 'as soon as possible.' Otherwise, here are some ways to incorporate COVID vaccine recommendations both in and outside the clinic:
Yahoo
28 minutes ago
- Yahoo
Mass rollout of weight loss jabs begins on NHS today - are you eligible?
An NHS mass rollout of weight loss jabs Mounjaro on the NHS in England will begin on Monday as GPs are allowed to prescribe the drugs for the first time. Around 220,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years. Around 29% of the adult population in the UK is obese. The drug is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested. From today, GPs in England will be allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health problems. Patients previously needed to access the drugs through a special weight loss service. But leading family doctors said some GPs have expressed concern about the additional workload linked to the rollout. Coming up on GMB 👇 📰 There are fears that the UK will face terror attacks as Iran vows revenge on America and its allies. 📰 The mass rollout of the weight-loss jab Mounjaro on the NHS in England begins today, but GPs and pharmacists warn of increased workloads and a lack of… — Good Morning Britain (@GMB) June 23, 2025 And pharmacy experts also said there could be pressure on supplies of the drug. In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. Dr Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today. 'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health – and greater access to weight loss drugs will make a significant difference to the lives of those people. 'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions. 'While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.' Recommended reading: Mounjaro heatwave warning as temperatures soar Mounjaro warning for anyone planning a holiday When will Mounjaro be rolled out on the NHS? Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'While we recognise the potential benefits of weight loss drugs, we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments. 'The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. As and when this is escalated, appropriate resourcing for general practice – including access to 'wraparound' services – and training for GPs must follow. She added: 'GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely. 'More widely, whilst weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. 'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.' Dr Hawthorne said there is no 'one size fits all approach' and that the rollout of the jabs should not 'come at the expense of other weight loss service'. She continued: 'The roll-out of weight loss medications in the NHS will need to be consistently evaluated to ensure that there is evidence that these prescriptions are of long-term benefit to patients.' Olivier Picard, chairman of the National Pharmacy Association, said: 'The demand for weight loss jabs continues to rise sharply, and more GPs have been directing patients back to pharmacies after initial inquiries, to access these treatments privately. 'As the NHS is now moving to implement National Institute for Health and Care Excellence (Nice) guidance, and tirzepatide becomes prescribable to more patients, we expect to see prescription volumes increase rapidly. 'However, NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy. 'Pharmacists are experts in medication and many of us have lots of experience delivering weight loss injections as part of a package of care including lifestyle advice. 'We are well placed to help roll out weight loss treatment on the NHS, with the right funding to support it. 'The biggest concern we have is that prescribing these medications alone misses the point. 'They should be part of a comprehensive weight management strategy – combining lifestyle coaching, exercise, and nutritional guidance. In reality, many GPs lack the bandwidth to deliver the level of support needed to ensure proper understanding and follow-up. 'As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends – simply because the foundational lifestyle changes weren't addressed.'
Yahoo
37 minutes ago
- Yahoo
This Startup Is Disrupting Traditional Tech Outsourcing With AI-Powered Teams
SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- As global IT spending heads toward an estimated $5.74 trillion in 2025, one aspect of the sector remains largely unchanged: the outsourcing model. Even with the rapid advancements in AI technology, many IT service providers still rely on a decades old playbook - one that emphasizes headcount, billable hours, and one-size-fits-all delivery. A startup founded in 2018, EMB Global, is betting that the future looks very different. The company, which has raised over $25 million to date and operates across 23 countries, has built a delivery framework that blends proprietary artificial intelligence with highly specialized human expertise. Its goal: to replace static, resource-heavy outsourcing with leaner, faster, and more adaptive teams. At the center of EMB's model is Aura, a proprietary AI agent powered by Small Language Models (SLMs) trained on industry-specific and regionally contextual datasets. According to the company, Aura now automates up to 80% of key functions, from requirement gathering to project management workflows, dramatically reducing manual overhead and time to delivery. Human expertise still plays a critical role. EMB Global works with a distributed network of more than 1,500 boutique agencies, each selected for domain alignment, allowing the company to bring both speed and specificity to projects across sectors like fintech, healthcare, logistics, and retail. "We're not in this to deliver code," says Rohan Barua, Co-founder of EMB Global and a Forbes 30 Under 30 Asia honoree. He is blunt about the state of the industry. "The legacy outsourcing model was built for a different era-one where inefficiency was profitable and nuance didn't matter. That doesn't cut it anymore." As EMB expands into the U.S. market, its positioning is clear: fewer layers, faster execution, and solutions built around real business goals-not headcount. "I've spoken to our customers and found out that, on average, we helped them reduce delivery times by 52% and cut costs by around 35%," says Nishant Behl, Founder and CEO of EMB Global. A member of the Forbes Technology Council, he adds, "But more importantly, we're giving them tech capabilities that were once the exclusive domain of tech giants." Of the company's total funding, $5 million has been set aside specifically to scale its AI infrastructure, which is a part of a broader effort to support growing demand for personalized, high-impact technology partnerships. The company has also earmarked an additional $25 million over the next two years to accelerate the development and deployment of its AI capabilities. With global enterprise AI spend projected to reach $644 billion by 2025, a 76.4% increase over 2024, EMB Global is carving out a distinct space in the market - where automation is intelligently paired with deep, domain-specific expertise. "Our objective," Behl adds, "is to make advanced technology not just available, but usable, cost-effective, context-aware, and aligned with tangible business outcomes." For more information, visit Media Contact: Ata Suhail | Logo: View original content to download multimedia: SOURCE EMB Global
